Mylan's most recent trend suggests a bullish bias. One trading opportunity on Mylan is a Bull Put Spread using a strike $46.00 short put and a strike $41.00 long put offers a potential 12.11% return on risk over the next 9 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $46.00 by expiration. The full premium credit of $0.54 would be kept by the premium seller. The risk of $4.46 would be incurred if the stock dropped below the $41.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Mylan is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Mylan is bullish.
The RSI indicator is at 62.34 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Mylan
Mylan Schedules Fourth Quarter and Year End 2013 Financial Results Conference Call and Live Webcast
Tue, 11 Feb 2014 15:20:00 GMT
PR Newswire – PITTSBURGH, Feb. 11, 2014 /PRNewswire/ — Mylan Inc. (MYL) announced today that it will host a conference call and live webcast, including a slide presentation, on Thursday, Feb. 27, 2014, at 10:00 a.m. ET, to review the company's financial results for the fourth quarter and year ended Dec. 31, 2013. The company also will be providing its financial guidance for 2014. Mylan will release its financial results on Feb. 27 before the market opens. The dial-in number to access the call is 800.514.4861 or 678.809.2405 for international callers. A replay, available for approximately seven days, will be available at 855.859.2056 or 404.537.3406 for international callers;
Generic-Drug Makers Actavis, Mylan To Report Q4 Soon
Mon, 10 Feb 2014 22:40:00 GMT
Roche bans rivals from comparing copycat drugs to Herceptin
Fri, 07 Feb 2014 16:33:44 GMT
Reuters – Pharmaceutical group Roche said it secured an injunction from an Indian court banning generic drug makers Biocon and Mylan from comparing their copycat versions of Roche's Herceptin breast cancer treatment to the original. Mylan and Biocon, which co-developed breast cancer drugs CANMab and Hertraz they say are biosimilars of Herceptin, are no longer allowed to refer to Herceptin or its manufacturing process, safety, efficacy and sales when communicating about their drugs, the New Delhi High Court ruled on Wednesday.
Pfizer beats back generic competition for Lyrica
Thu, 06 Feb 2014 18:01:17 GMT
Reuters – Pfizer Inc, the world's largest drugmaker, has beaten back generic competition for the pain medicine Lyrica, its biggest product, with a U.S. appeals court ruling that competing generic products would infringe on the company's patents. The U.S. Court of Appeals for the Federal Circuit, which handles all patent appeals, ruled on Thursday that Teva Pharmaceuticals USA Inc, Lupin Ltd, Actavis Inc and other generic competitors had infringed on Pfizer's patents. The decision upholds a ruling by the U.S. District Court for the District of Delaware that said that the generic versions may not be sold.
Mylan Rolls out Herceptin Biosimilar in India
Mon, 03 Feb 2014 16:10:04 GMT
Also on Market Tamer…
Follow Us on Facebook